Jci_page_head_homepage_01 Jci_page_head_homepage_02
Tianfu Wu, Xiangmei Qin, Zoran Kurepa, Kirthi Raman Kumar, Kui Liu, Hasna Kanta, Xin J. Zhou, Anne B. Satterthwaite, Laurie S. Davis, Chandra Mohan
Published in Volume 117, Issue 8
J Clin Invest. 2007; 117(8):2186–2196 doi:10.1172/JCI30398
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9
Impact of mTOR blockade on B6.Sle1z.Sle3z lupus.

Shown are changes in spleen weight (A), total splenocyte counts (B), percentage change in the numbers of different splenic cell subsets (C), anti-nuclear autoantibodies as determined by ELISA (DG), proteinuria (H), blood urea nitrogen (BUN) (I), and kidney pathology (J). GN, glomerulonephritis; P, placebo; R, RAD001; d, days after treatment. P values shown pertain to a Student’s t test comparison of the RAD001-treated congenic samples with the placebo-treated congenic samples.